Covid-19 vaccine potentially moves a step closer

The video discusses SNG 001, a drug that converts into a mist for inhalation, potentially preventing COVID-19 progression. Administered via a nebulizer, it delivers interferon beta to the lungs, boosting antiviral responses. Initial trials with 101 volunteers show promise, but results are not yet peer-reviewed. Larger trials are needed to confirm efficacy. If successful, SNG 001 could reduce the need for mechanical ventilation and alter COVID-19 treatment dynamics. The drug's availability during a potential second wave is anticipated, pending regulatory approval.

What is the significance of the trials being conducted on a small number of volunteers?

What caution does Professor Stephen Evans advise regarding the results of the trials?